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Abstract
Benzodiazepines (BZs) are safe drugs for treating anxiety, sleep, and seizure disorders, but their use also results in
unwanted effects including memory impairment, abuse, and dependence. The present study aimed to reveal the
molecular mechanisms that may contribute to the effects of BZs in the hippocampus (HIP), an area involved in drug-
related plasticity, by investigating the regulation of immediate early genes following BZ administration. Previous
studies have demonstrated that both brain derived neurotrophic factor (BDNF) and c-Fos contribute to memory- and
abuse-related processes that occur within the HIP, and their expression is altered in response to BZ exposure. In the
current study, mice received acute or repeated administration of BZs and HIP tissue was analyzed for alterations in
BDNF and c-Fos expression. Although no significant changes in BDNF or c-Fos were observed in response to twice-
daily intraperitoneal (i.p.) injections of diazepam (10 mg/kg + 5 mg/kg) or zolpidem (ZP; 2.5 mg/kg + 2.5 mg/kg),
acute i.p. administration of both triazolam (0.03 mg/kg) and ZP (1.0 mg/kg) decreased BDNF protein levels within the
HIP relative to vehicle, without any effect on c-Fos. ZP specifically reduced exon IV-containing BDNF transcripts with
a concomitant increase in the association of methyl-CpG binding protein 2 (MeCP2) with BDNF promoter IV,
suggesting that MeCP2 activity at this promoter may represent a ZP-specific mechanism for reducing BDNF
expression. ZP also increased the association of phosphorylated cAMP response element binding protein (pCREB)
with BDNF promoter I. Future work should examine the interaction between ZP and DNA as the cause for altered
gene expression in the HIP, given that BZs can enter the nucleus and intercalate into DNA directly.
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Introduction
Benzodiazepines (BZs) and related drugs such as zolpidem
increase GABA-mediated inhibition via positive allosteric
modulation of GABAA receptors throughout the central nervous
system [1]. This drug class is commonly prescribed for treating
anxiety, sleep, and seizure disorders, and while clinically
valuable, their use can result in undesirable effects including
memory impairment as well as abuse and dependence [2,3].
Given their widespread application, understanding more fully
how BZs produce their effects is an important public health
issue that will provide a framework for designing novel
compounds to overcome their limitations as therapeutics.
A recent study using functional imaging to visualize global
drug action within the brain suggested that alterations in
coordinated brain activity within networks of brain regions may
underlie the changes in observable behavior induced by BZ-
like drugs [4]. Meanwhile, the cell surface interactions between
BZs and specific subtypes of the GABAA receptor has been
shown to be critically important for determining the behavioral
response to these drugs [5]. Together, network and receptor
mechanisms contribute to our understanding of how BZs affect
behavior, but there is a gap in our knowledge regarding the
molecular substrates mediating the effects of this drug class.
Previous studies have provided the foundation for examining
the influence of BZs on intracellular processes and signaling
cascades by showing that proteins involved in regulating
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synaptic function and plasticity are sensitive to BZ challenge
[6-8]. Accordingly, changes in immediate early gene expression
[9-14] have been observed following BZ treatment. Brain-
derived neurotrophic factor (BDNF) and c-Fos are of particular
interest in this regard given that both are reduced by BZ
exposure [6,9,15-17], although contradictory results have been
reported [18]. Further, both are implicated in learning- [19,20]
and drug abuse-related [21-23] neuronal plasticity. Together,
their importance in brain function and the modulation of their
expression by BZs, suggests that examining BDNF and c-Fos
may provide insight that will be informative for clarifying the
molecular mechanisms of BZ action.
The present study investigated the regulation of BDNF and
c-Fos following administration of the BZs triazolam (TZ) and
diazepam (DZ), as well as zolpidem (ZP), which is structurally
distinct but BZ-like in its mechanism of action. It was
hypothesized that understanding how administration of BZ-like
drugs affects immediate early gene expression would reveal
potential points of intervention for influencing the regulation of
key proteins as strategies for avoiding or ameliorating the
limiting effects BZs. Acute and repeated drug challenges were
employed to replicate and extend previous findings [6,9-17].
Results indicated that while there was a significant reduction in
BDNF protein in the hippocampus (HIP), an area involved in
drug-related plasticity [24], there was no change in c-Fos
levels. Consequently, the study focused on BZ-induced
regulation of the BDNF gene.
Methods
Ethics Statement
These studies were approved by the Institutional Animal
Care and Use Committees of the Harvard University Medical
School (Protocol 04184) and McLean Hospital (#11-10/2-6),
and they were conducted according to the Guide for the Care
and Use of Laboratory Animals (NIH publication no. 85–23,
revised 1996).
Animals
A total of 134 (62 acute and 72 repeated) male C57BL/6J
(four to six weeks of age) were group housed in a temperature-
and humidity- controlled facility with a 12 hour light/dark cycle
(lights on at 7AM). All animals were provided with water and
food ad libitum. Mice were handled and habituated to the
housing room for at least one week prior to drug treatment.
Mice in the acute treatment group were randomly assigned to
receive a single injection of TZ (0.03 mg/kg), ZP (1.0 mg/kg), or
vehicle (VEH; 80% propylene glycol/20% sterile water) [25],
and they were sacrificed within 30 min of treatment [26]. Those
mice in the repeated treatment group were randomly assigned
to receive twice-daily injections (10 am and 4 pm) of DZ (10
mg/kg + 5 mg/kg), ZP (2.5 mg/kg + 2.5 mg/kg), or VEH (10%
cyclodextrin in sterile water) over the course of seven
consecutive days [27,28], and they were sacrificed 60 min after
the last injection. All injections were via the intraperitoneal
route and in a volume of 0.01 ml/g. At the conclusion of the
injection paradigm, animals were euthanized with CO2 followed
by decapitation. After sacrifice all brains were removed quickly
and the hippocampi were dissected. Tissue was flash frozen
using 2-methylbutane and maintained at -80° C.
Western Blotting
Whole cell extracts from dissected brain tissue were used for
blots as described previously [29,30]. Briefly, 20 μg of each
sample was boiled in the presence of sample buffer for 5 min
before separation on 10-20% SDS-polyacrylamide gel. Proteins
were transferred to nitrocellulose membranes. The
immunoblots were blocked with 5% nonfat dry milk dissolved in
Tris-buffered saline containing 0.2% Tween 20 (TBST) for 60
min. The membranes were incubated overnight at 4° C with
specific antibodies including anti-BDNF 1:700 (Aviva Systems
Biology), anti-TrkB 1:600 (Santa Cruz), anti-cFos 1:400
(Abcam), anti- phosphorylated cAMP response element binding
protein (pCREB, Ser 133) 1:500 (Millipore), anti-CREB 1:700
(Abcam), anti-di-acetyl lysine 9, lysine14 histone H3
(H3K9K14Ac2; AcH3) 1:1000 (Millipore), anti-Methyl-CpG
binding protein 2 (MeCP2) 1:500 (Abcam), and anti-GAPDH
1:1000 (Abcam). Primary antibody incubation was followed by
six washes (10 min, rocking at room temperature) in TBST
before incubation with the secondary antibody (HRP-
conjugated goat anti-rabbit IgG; Jackson ImmunoResearch
Laboratories), followed by visualization using the enhanced
chemiluminescence detection system (NEN).
Enzyme-Linked Immunosorbant Assay (ELISA)
Brain tissue was lysed, homogenized, and diluted to 20 μg/μl
in order to quantify the concentration of BDNF using the
Chemikine™ BDNF Sandwich ELISA kit (Chemicon
International Inc.). The tissue samples and serial dilutions of
BDNF standards were loaded in triplicate onto a microplate
coated with rabbit anti-mouse BDNF polyclonal antibodies and
incubated overnight at 4° C. After four washes, biotinylated
mouse anti-mouse BDNF monoclonal antibody (1:1000) was
added for 2.5 h at room temperature. The plates were washed
four times, strepavidin-enzyme conjugate was added, and
plates incubated for 1 h. After further washing,
tetramethylbenzidine chromagenic substrate was added and
the reaction was stopped after 15 min. The absorbance at 450
nm was measured with a plate reader, and BDNF
concentration in the tissue was assessed by comparing values
to the prepared standard curve.
RNA Extraction and Reverse Transcription
RNA was extracted using the RNeasy kit (Qiagen) according
to manufacturer’s instructions and as described previously
[29,30]. Reverse transcription reactions were performed using
the Superscript First Strand Synthesis System for RT-PCR
reactions (Invitrogen) using specific primers to quantify the
amount of gene expression as compared to a standard curve.
Primers included GAPDH and BDNF as previously published
sequences [30-32]. Quantitative real time-PCR was performed
in an iCycler (Bio-Rad) using SYBR-green PCR Master Mix
(Applied Biosystems) through 50 PCR cycles (95° C for 30 s,
57° C for 60 s, 72° C for 90 s). The threshold cycle for each
sample was chosen from the linear range and converted to a
starting quantity by interpolation from a standard curve run on
Benzodiazepine Effects on BDNF
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the same plate for each set of primers. Levels of mRNA were
normalized to GAPDH.
Chromatin Immunoprecipitation (ChIP)
The ChIP technique was used to analyze DNA/protein
complexes in the dissected brain tissue. Protocols were
adapted and modified from previously published studies [33,34]
and described extensively in recent work [30,32]. Briefly, the
tissue underwent a formaldehyde cross-linking step to link the
proteins of interest to DNA. Samples then were homogenized
and subjected to immunoprecipitation with 5 µg of antibodies
specific for Methyl-CpG binding protein 2 (MeCP2; Abcam), di-
acetyl lysine 9, lysine14 histone H3 (H3K9K14Ac2; AcH3;
Millipore), or pCREB (Abcam). The antibody-transcription
factor-DNA complexes were washed to reverse the crosslinks,
and the DNA was detected by qPCR using specific primers for
the multiple BDNF promoters. Threshold amplification cycle
numbers (Tc) using iCycler software were used to calculate IP
DNA quantities as percentage of corresponding inputs. The
exon-specific BDNF primers were designed based on
previously published sequences [35-37] and used for real-time
PCR analysis.
Data Analyses
For western blot analyses integrated density values (% IDV)
were calculated by dividing the density values for the protein of
interest by the density values for GAPDH for each sample.
Transcript levels also were analyzed as a percentage of
GAPDH. Data then were analyzed with ANOVAs to examine
treatment effects. Post-hoc pairwise comparisons were
performed with Bonferroni to assess treatment effects at a
significance level of p< 0.05.
Results
A number of measurements were obtained following acute or
repeated treatment with two classical BZs, TZ and DZ, as well
as the BZ-like hypnotic ZP. All three drugs bind to a site on the
native pentameric GABAA receptor that is situated between the
γ2 subunit and an α subunit, but while the classical BZs are
non-selective and will bind α1, α2, α3, or α5 subunit-containing
receptors [38,39], ZP exhibits relatively selective affinity for
GABAA receptors containing an α1 subunit [40,41].
Levels of c-Fos and BDNF protein were measured by
western blots and analyzed with one-way ANOVAs. While
acute BZ treatment had no significant effect on c-Fos relative to
VEH (Figure 1A & B), there was a significant decrease in
BDNF following acute treatment with both ZP and TZ in the HIP
[F(2,9)= 4.57, p= 0.043] (Figure 1A & C). This observation was
confirmed with ELISA, which also demonstrated a significant
reduction in BDNF protein levels in the HIP following acute ZP
and TZ [F(2,9)= 9.568, p= 0.006] (Figure 1D).
The BDNF gene is comprised of eight untranslated 5′ exons
that are spliced onto the coding 3′ exon containing the coding
domain used to generate multiple mRNAs [31,42,43]. The
function of these transcripts is not known, however, their
expression pattern differs between brain nuclei and they are
differentially targeted and translated within cells. A two-way
ANOVA examining the expression of BDNF exon I, II, IV, and
VI-containing transcripts in the HIP following BZ treatment
indicated that not only do the amounts of the four transcripts
vary within this brain region as illustrated by the white bars
representing VEH in Figure 2 [F(3, 55)= 16.05, p< 0.0001], but
there was a significant main effect of treatment [F(2, 55)= 3.26, p=
0.046]. Specifically, there was a significant decrease in BDNF
exon IV-containing transcript levels following acute treatment
with ZP (p< 0.01; Figure 2).
Because acute BZ treatment reduced BDNF levels in the
HIP, the molecular mechanisms by which BZs regulate BDNF
expression were investigated. Given that gene expression is
influenced by sequence-specific binding of transcription factors
to promoter regions, it was hypothesized that BZ-induced
decreases in BDNF levels in the HIP resulted from alterations
in the assembly of transcription factors at BDNF promoters.
BDNF gene expression is regulated by the activity of a number
of transcription factors, including CREB and MeCP2 [35,37,44].
Therefore, changes in pCREB (phosphor-Ser133; the activated
form of CREB) and MeCP2 in response to acute BZ treatment
were measured next.
CREB is known to regulate the expression of promoter I- and
IV-containing BDNF transcripts [35,44], therefore it was
predicted that BZs would decrease pCREB. Although one-way
ANOVA indicated there were no statistically significant changes
in total CREB [F(2,9)= 1.99, p= 0.183] or overall levels of pCREB
Figure 1.  BDNF levels are decreased following acute BZ
treatment.  (A) Representative immunoblots for c-Fos, BDNF,
and GAPDH, as well as Coomassie gel representing the
loading control for VEH, ZP, or TZ-treated HIP; (B) There is no
change in c-Fos protein levels following BZ treatment as
measured by western blots (n= 3). (C) There is a significant
decrease in BDNF levels in the HIP following ZP and TZ
treatment as measured by western blots (n= 4); (D) There is a
significant decrease in BDNF levels following BZ treatment as
measured by ELISA (n= 3-6). * p< 0.05; IDV: integrated density
values.
doi: 10.1371/journal.pone.0084806.g001
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(normalized to total CREB) following treatment [F(2,9)= 0.134, p=
0.877] (Figure 3A), global pCREB levels do not represent
action at individual gene promoters. Therefore, ChIP was used
to assess alterations in pCREB binding to BDNF promoters.
Two-way ANOVA examining drug effects on the association
with promoters I or IV indicated a significant increase in pCREB
binding to BDNF exon I promoter following ZP treatment
[F(2,27)= 5.65, p= 0.009] such that the association following
zolpidem specifically was greater than that for VEH and TZ (p<
0.05; Figure 3B).
MeCP2 repression of BDNF promoter IV has been well
described in previous studies [30,35,37]. A requisite step in
BDNF promoter IV-containing gene expression is de-
repression caused by the dissociation of MeCP2 from promoter
IV [35]. Based on the observed reduction in BDNF promoter IV
transcript in response to ZP, it was predicted that ZP would
increase MeCP2 association at this specific promoter. One-way
ANOVA indicated no change in overall levels of MeCP2 in the
HIP [F(2,6)= 0.33, p= 0.729] (Figure 4A). However, two-way
ANOVA revealed a significant increase in the association of
MeCP2 with BDNF exon IV promoter in the HIP following acute
treatment with ZP as measured by ChIP [F(1,9)= 6.09, p= 0.036]
(Figure 4B).
Chromatin remodeling through modification of histone
proteins is another requisite mechanism for gene expression.
In general, histone acetylation is a modification that relaxes
chromatin and corresponds to increased transcription; thus, we
predicted that a decrease in acetylation may underlie the
observed decrease in BDNF levels within the HIP following
acute treatment. As shown in Figure 5A, one-way ANOVA
indicated no change in overall AcH3 protein levels in the HIP
as measured by western blots [F(2,6)= 0.12, p= 0.887]. Because
global alterations in histone proteins do not necessarily
translate into changes in histone association with specific gene
promoters, ChIP was used next to assess the extent to which
BZ treatment altered AcH3 association with BDNF promoters
as a putative mechanism underlying the decrease in BDNF
expression in the HIP. The ChIP assay revealed no significant
Figure 2.  BDNF exon IV-containing transcript is decreased
following acute ZP treatment.  There is a selective and
significant decrease in BDNF exon IV-containing transcript
following ZP treatment compared to VEH in the HIP (n= 4-7). **
p < 0.01.
doi: 10.1371/journal.pone.0084806.g002
changes in the association of AcH3 with BDNF promoters as
two-way ANOVA indicated no significant main effects of
treatment (p= 0.766) or transcripts (p= 0.621; Figure 5B).
One-way ANOVAs demonstrated that neither acute ZP nor
acute TZ had an effect on TrkB receptor [F(2,6)= 2.00, p= 0.22]
protein levels as measured by western blots (data not shown).
Moreover, chronic injections of ZP or DZ had no effect on
BDNF protein levels compared to VEH [F(2,21)= 0.15, p= 0.87].
Examination of the activity-related proteins c-Fos [F(2,12)= 0.09,
p= 0.92] and pCREB [F(2,12)= 0.89, p= 0.44] also indicated no
effect of treatment in the repeated condition (data not shown).
For this reason MeCP2, AcH3, and TrkB protein, as well as
exon-specific mRNA levels, were not examined in the tissue.
Figure 3.  pCREB levels in the HIP following acute BZ
treatment.  (A) There is no change in total pCREB protein
levels in the HIP following BZ treatment as measured by
western blots (n= 4); (B) There is a significant increase in
pCREB association with BDNF promoter I in the HIP following
ZP treatment as measured by ChIP (n= 5-7). * p< 0.05; IDV:
integrated density values.
doi: 10.1371/journal.pone.0084806.g003
Benzodiazepine Effects on BDNF
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Discussion
In the present study, acute administration of both TZ and ZP
resulted in decreases in BDNF protein levels within the HIP. ZP
specifically reduced exon IV-containing BDNF transcripts with a
concomitant increase in the association of MeCP2 with BDNF
promoter IV, while also increasing the association of pCREB
with BDNF promoter I. No significant effects were observed in
response to chronic BZ treatment.
BDNF was hypothesized as a candidate for contributing to
the effects of BZs because of its importance in psychoactive
Figure 4.  Increased MeCP2 association with BDNF
promoter IV in the HIP following acute BZ treatment.  (A)
There is no change in total MeCP2 protein levels in the HIP
following BZ treatment as measured by western blots (n= 3);
(B) There is a significant increase in MeCP2 association with
BDNF promoter IV in the HIP following ZP treatment as
measured by ChIP (n= 3-4). * p< 0.05; IDV: integrated density
values.
doi: 10.1371/journal.pone.0084806.g004 drug action in general [45-47] and processes related to abuse
and dependence [23] and learning and memory [20]
specifically. The data presented here agree with previous
findings implicating BDNF in the acute effects of BZs [6,15-17],
although repeated drug administration failed to influence BDNF
expression. Given that TZ and ZP are known to have
deleterious effects on memory when administered acutely [48],
a potential explanation for a reduction in BDNF following acute
drug administration is that these changes may provide the
foundation for drug-induced memory deficits. This
interpretation, while speculative without concurrent behavioral
outcomes, is consistent with a number of studies showing the
blockade of hippocampal long-term potentiation [49-52] or the
Figure 5.  No change in histone acetylation in the HIP
following acute BZ treatment.  (A) There is no change in total
AcH3 protein levels in the HIP following BZ treatment as
measured by western blots (n= 3); (B) There is no change in
AcH3 association with BDNF promoters in the HIP following ZP
treatment as measured by ChIP (n= 4). IDV: integrated density
values.
doi: 10.1371/journal.pone.0084806.g005
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acquisition of fear conditioning [53 and references therein] by
BZs. While ZP once was believed to engender fewer memory
impairing effects relative to its non-selective counterparts
[54,55], it has since been shown to possess LTP-blocking
activity as well [56]. These outcomes are consistent with
immunohistochemical data showing that in the HIP there is an
abundance of the ZP-specific GABAA receptor subtype (i.e.,
those containing an α1 subunit) in addition to those with lower
ZP binding affinity [57,58], all of which provide binding sites for
the classical BZs.
Another possible interpretation for drug-induced changes in
BDNF involves stress-related mechanisms within the brain.
Reductions in BDNF [59-61] and mRNA for BDNF exons I and
IV [62] have been shown to result from acute exposure to a
stressor, suggesting that the inhibitory drug treatment may
induce a stress response. While the previously demonstrated
reductions in exon-specific mRNA were accompanied by
reduced acetylation levels [62] which we did not observe here,
the idea of initiating a stress response is consistent with studies
showing that BZs and ZP especially, have the ability to activate
the hypothalamic-pituitary-adrenocortical axis and elevate
plasma corticosterone levels in rodents [63,64]. Moreover, this
idea is consistent with work showing that an increase in HIP
BDNF associated with a neurogenic antidepressant response
[65] was blocked by BZ administration [66,67].
Although both acute drug treatments reduced BDNF, they
did not exhibit clear effects on pCREB with the exception of the
dramatic ZP-induced increase in pCREB association with
BDNF promoter I. While this interaction is in agreement with a
previous study demonstrating a BZ-induced increase in pCREB
levels in mouse brain extract [8], the present result suggests
that a drug-activity relationship may exist, perhaps mediated
via GABAA receptors containing an α1 subunit specifically.
Alternatively, observed effects on pCREB and its association
with BDNF promoters may be non-specific and irrelevant to the
ability of BZs to modulate BDNF. BZs have been shown to bind
to central receptors located within the nucleus [68,69],
suggesting that they may be able to bypass the immediate
early genes and affect gene expression through a direct
interaction with DNA. This idea is supported by a study
demonstrating the ability of a BZ to intercalate into DNA,
resulting in a more stable and compact DNA conformation [70].
Therefore, it is possible that this type of BZ-induced structural
change or interaction may prevent access to the gene and
hinder the transcriptional machinery, thus providing a
mechanism to explain the reduction in BDNF without the
involvement of CREB or histone acetylation. Recently it has
been shown that BZs are potent inhibitors of bromodomain and
extra-terminal (BET) family of transcriptional co-regulators
[71,72]. Bromodomain-containing proteins are epigenetic
readers associated with open chromatin architecture and
transcriptional activation [73]. Inhibition of BET proteins,
therefore, is another potential mechanism whereby BZs can
alter the expression of genes such as BDNF.
Though there were no significant changes in pCREB or
acetylated histone association with BDNF promoters in
response to acute BZ treatment, there was a significant ZP-
induced increase in MeCP2 binding to BDNF exon IV promoter.
Given the significant decrease in BDNF exon IV-containing
transcript levels following ZP treatment, increases in MeCP2 at
this promoter may represent an underlying mechanism
whereby ZP specifically reduces BDNF expression. Indeed,
previous studies have demonstrated that removal of MeCP2
from BDNF promoter IV is involved in the activity-dependent
increase in the expression of BDNF exon IV-containing
transcripts [35,37]. Further, NMDA receptor stimulation of
cultured HIP neurons increased phosphorylation of MeCP2, its
dissociation from the promoter, and increased BDNF exon IV
transcript levels [74]. Considering that GABA maintains the
balance between excitation and inhibition as evidenced by BZ
blocking of NMDA-related activity [75-77], ZP’s ability to
enhance GABAergic neurotransmission may oppose
glutamatergic activity, thus keeping MeCP2 bound to the BDNF
promoter. In addition, increased MeCP2 binding may represent
an indirect measure of increases in DNA methylation of CpG
islands which are the binding sites for MeCP2. Because
MeCP2 binds methylated cytosines, the implication of our
finding is that association of MeCP2 to BDNF promoter IV
results from a ZP-induced increase in DNA methylation. This
idea is speculative, but it provides a rationale for further study.
In the present study, c-Fos expression was unaltered by
either acute or repeated BZ treatment. However, unlike the
consistent reduction in BDNF reported in previous work
[6,15-17], the expression of c-Fos was not altered reliably by
BZs. For instance, while DZ-induced reductions in c-Fos mRNA
were observed in the cortex as well as the HIP [6,9], several
others reported DZ-induced increases [12,13] or no change in
rodent brain tissue [12,78] or cell lines [10]. Considering that a
prominent mechanism for influencing transcription of the c-fos
gene occurs via a pCREB pathway [79] and pCREB was
unchanged here, our results are consistent with one another as
well as with the body of literature indicating no early effect of
BZs on c-Fos [10,12,78].
Examination of intracellular drug-induced alterations was
expected to provide further insight regarding the effects of BZs,
especially because previous research had implicated several
proteins involved in the regulation of synaptic function and
plasticity as being important for mediating those effects
[6-8,15-17]. However, other work examining GABAergic drugs
including muscimol [17,80], bicuculline [81], and ethanol [82],
suggests that interpreting the effects on BDNF and exon-
specific mRNA may not be attributable to BZs in particular, but
modulation of GABAA receptors in general. While our results
would provide the foundation for arguing that the modulation of
GABAA receptors containing an α1 subunit specifically is
important, the overall significance of these inhibition-induced
alterations and why they are observed only following acute
treatment still is unknown. Future work examining the
interaction between ZP and DNA as the cause for altered
BDNF expression in the HIP is warranted.
Author Contributions
Conceived and designed the experiments: SCL UR JKR GSV.
Performed the experiments: SCL NMS MNH SBD GRS GSV.
Analyzed the data: SCL MNH SBD GRS GSV. Contributed
reagents/materials/analysis tools: UR JKR GSV. Wrote the
Benzodiazepine Effects on BDNF
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e84806
manuscript: SCL UR GSV. Managed protocols: UR JKR.
Prepared data for presentation: MNH SBD GRS.
References
1. Tallman JF, Thomas JW, Gallager DW (1978) GABAergic modulation
of benzodiazepine binding site sensitivity. Nature 274: 383-385. doi:
10.1038/274383a0. PubMed: 27722.
2. Licata SC, Rowlett JK (2008) Abuse and dependence liability of
benzodiazepine-type drugs: GABAA receptor modulation and beyond.
Pharmacology Biochemistry, and Behavior 90: 74-89. doi:10.1016/
j.pbb.2008.01.001.
3. Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin
Psychiatry 66 [suppl 2]: 9-13. PubMed: 15762814.
4. Licata SC, Nickerson LD, Lowen SB, Trksak GH, MacLean RR et al.
(2013) The hypnotic zolpidem increases the synchrony of BOLD signal
fluctuations in widespread brain networks during a resting paradigm.
NeuroImage 70: 211-222. doi:10.1016/j.neuroimage.2012.12.055.
PubMed: 23296183.
5. Rudolph U, Möhler H (2006) GABA-based therapeutic approaches:
GABAA receptor subtype functions. Curr Opin Pharmacol 6: 18-23. doi:
10.1016/j.coph.2005.10.003. PubMed: 16376150.
6. Huopaniemi L, Keist R, Randolph A, Certa U, Rudolph U (2004)
Diazepam-induced adaptive plasticity revealed by α1 GABAA receptor-
specific expression profiling. J Neurochem 88: 1059-1067. doi:
10.1046/j.1471-4159.2003.02216.x. PubMed: 15009662.
7. Kim DH, Kim S, Jeon SJ, Son KH, Lee S et al. (2009) Tanshinone I
enhances learning and memory, and ameliorates memory impairment
in mice via the extracellular signal-regulated kinase signaling pathway.
Br J Pharmacol 158: 1131-1142. doi:10.1111/j.
1476-5381.2009.00378.x. PubMed: 19775283.
8. Saraf MK, Prabhakar S, Pandhi P, Anand A (2008) Bacopa monniera
ameliorates amnesic effects of diazepam qualifying behavioral-
molecular partitioning. Neuroscience 155: 476-484. doi:10.1016/
j.neuroscience.2008.05.043. PubMed: 18585439.
9. Bozas E, Tritos N, Phillipidis H, Stylianopoulou F (1997) At least three
neurotransmitter systems mediate a stress-induced increase in c-fos
mRNA in different rat brain areas. Cell Mol Neurobiol 17: 157-169. doi:
10.1023/A:1026309727518. PubMed: 9140695.
10. Fukuda K, Shoda T, Mima H, Uga H (2002) Midazolam induces
expression of c-Fos and EGR-1 by a non-gabaergic mechanism.
Anesth Analg 95: 373-378. PubMed: 12145054.
11. Malkani S, Rosen JB (2000) Differential expression of EGR-1 mRNA in
the amygdala following diazepam in contextual fear conditioning. Brain
Res 860: 53-63. doi:10.1016/S0006-8993(00)01976-4. PubMed:
10727623.
12. Niles LP, Smith LJ, Tenn CC (1997) Modulation of c-fos expression in
the rat striatum by diazepam. Neurosci Lett 236: 5-8. doi:10.1016/
S0304-3940(97)00755-6. PubMed: 9404938.
13. Salminen O, Lahtinen S, Ahtee L (1996) Expression of Fos protein in
various rat brain areas following acute nicotine and diazepam.
Pharmacol Biochem Behav 54: 241-248. doi:
10.1016/0091-3057(95)02132-9. PubMed: 8728564.
14. Thompson BL, Rosen JB (2006) Immediate-early gene expression in
the central nucleus of the amygdala is not specific for anxiolytic or
anxiogenic drugs. Neuropharmacology 50: 57- 68. doi:10.1016/
j.neuropharm.2005.07.024. PubMed: 16185722.
15. Huang TL, Hung YY (2009) Lorazepam reduces the serum brain-
derived neurotrophic factor level in schizophrenia patients with
catatonia. Progress in Neuropsychopharmacol and Biological
Psychiatry 33: 159-159.
16. Kellogg CK, Yao J, Pleger GL (2000) Sex-specific effects of in utero
manipulation of GABA(A) receptors on pre- and postnatal expression of
BDNF in rats. Brain Research. Developmental Brain Research 121:
157-167. doi:10.1016/S0165-3806(00)00039-0. PubMed: 10876028.
17. Zafra F, Castrén E, Thoenen H, Lindholm D (1991) Interplay between
glutamate and gamma-aminobutyric acid transmitter systems in the
physiological regulation of brain-derived neurotrophic factor and nerve
growth factor synthesis in hippocampal neurons. Proc Natl Acad Sci U
S A 88: 10037-10041. doi:10.1073/pnas.88.22.10037. PubMed:
1658793.
18. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter
LE et al. (2008) Differential regulation of central BDNF protein levels by
antidepressant and non-antidepressant drug treatments. Brain Res
1211: 37-43. doi:10.1016/j.brainres.2008.03.023. PubMed: 18433734.
19. Guzowski JF (2002) Insights into immediate-early gene function in
hippocampal memory consolidation using antisense oligonucleotide
and fluorescent imaging approaches. Hippocampus 12: 86-104. doi:
10.1002/hipo.10010.abs. PubMed: 11918292.
20. Lu B, Chow A (1999) Neurotrophins and hippocampal synaptic
transmission and plasticity. J Neurosci Res 58: 76-87. doi:10.1002/
(SICI)1097-4547(19991001)58:1. PubMed: 10491573.
21. Chang SL, Squinto SP, Harlan RE (1988) Morphine activation of c-fos
expression in rat brain. Biochem Biophys Res Commun 157: 698-704.
doi:10.1016/S0006-291X(88)80306-1. PubMed: 3144275.
22. Marie-Claire C, Laurendeau I, Canestrelli C, Courtin C, Vidaud M et al.
(2003) Fos but not Cart (cocaine and amphetamine regulated
transcript) is overexpressed by several drugs of abuse: a comparative
study using real-time quantitative polymerase chain reaction in rat
brain. Neurosci Lett 345: 77-80. doi:10.1016/S0304-3940(03)00307-0.
PubMed: 12821175.
23. Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ (2009)
Neurotrophic factors and structural plasticity in addiction.
Neuropharmacology 56 Suppl 1: 73-82. doi:10.1016/j.neuropharm.
2008.06.059. PubMed: 18647613.
24. Eisch AJ, Harburg GC (2006) Opiates, psychostimulants, and adult
hippocampal neurogenesis: Insights for addiction and stem cell biology.
Hippocampus 16: 271-286. doi:10.1002/hipo.20161. PubMed:
16411230.
25. Sanger DJ, Joly D, Zivkovic B (1986) Effects of zolpidem, a new
imidazopyridine hypnotic, on the acquisition of conditioned fear in mice.
Psychopharmacology (Berl) 90: 207-210. PubMed: 2878460.
26. Benavides J, Peny B, Dubois A, Perrault G, Morel E et al. (1988) In
vivo interaction of zolpidem with central benzodiazepine (BZD) binding
sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential
affinity of zolpidem for the omega 1 (BZD1) subtype. J Pharmacol Exp
Ther 245: 1033-1041. PubMed: 2838599.
27. Elliott EE, White JM (2000) Precipitated and spontaneous withdrawal
following administration of lorazepam but not zolpidem. Pharmacology
Biochemistry, and Behavior 66: 361-369. doi:10.1016/
S0091-3057(00)00176-3.
28. van Rijnsoever C, Täuber M, Choulli MK, Keist R, Rudolph U et al.
(2004) Requirement of alpha5-GABAA receptors for the development
of tolerance to the sedative action of diazepam in mice. J Neurosci 24:
6785-6790. doi:10.1523/JNEUROSCI.1067-04.2004. PubMed:
15282283.
29. Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P et al. (2007)
Histones associated with downregulated genes are hypo-acetylated in
Huntington’s disease models. Hum Mol Genet 16: 1293-1306. doi:
10.1093/hmg/ddm078. PubMed: 17409194.
30. Sadri-Vakili G, Kumaresan V, Schmidt HD, Famous KR, Chawla P et
al. (2010) Cocaine-induced chromatin remodeling increases brain-
derived neurotrophic factor transcription in the rat medial prefrontal
cortex, which alters the reinforcing efficacy of cocaine. J Neurosci 30:
11735-11744. doi:10.1523/JNEUROSCI.2328-10.2010. PubMed:
20810894.
31. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T (2007) Mouse and
rat BDNF gene structure and expression revisited. J Neurosci Res 85:
525-535. doi:10.1002/jnr.21139. PubMed: 17149751.
32. Schmidt HD, Sangrey GR, Darnell SB, Schassburger RL, Cha JH et al.
(2012) Increased brain-derived neurotrophic factor (BDNF) expression
in the ventral tegmental area during cocaine abstinence is associated
with increased histone acetylation at BDNF exon I-containing
promoters. J Neurochem 120: 202-209. doi:10.1111/j.
1471-4159.2011.07571.x. PubMed: 22043863.
33. Braveman MW, Chen-Plotkin AS, Yohrling GJ, Cha JH (2004)
Chromatin immunoprecipitation technique for study of transcriptional
dysregulation in intact mouse brain. Methods Mol Biol 277: 261-276.
PubMed: 15201461.
34. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL
et al. (2006) Decreased association of the transcription factor Sp1 with
genes downregulated in Huntington’s disease. Neurobiol Dis 22:
233-241. doi:10.1016/j.nbd.2005.11.001. PubMed: 16442295.
35. Chen WG, Chang Q, Lin Y, Meissner A, West AE et al. (2003)
Derepression of BDNF transcription involves calcium-dependent
phosphorylation of MeCP2. Science 302: 885-889. doi:10.1126/
science.1086446. PubMed: 14593183.
36. Jiang X, Tian F, Du Y, Copeland NG, Jenkins NA et al. (2008) BHLHB2
controls Bdnf promoter 4 activity and neuronal excitability. J Neurosci
Benzodiazepine Effects on BDNF
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e84806
28: 1118-1130. doi:10.1523/JNEUROSCI.2262-07.2008. PubMed:
18234890.
37. Martinowich K, Hattori D, Wu H, Fouse S, He F et al. (2003) DNA
methylation-related chromatin remodeling in activity-dependent BDNF
gene regulation. Science 302: 890-893. doi:10.1126/science.1090842.
PubMed: 14593184.
38. Pritchett DB, Seeburg PH (1991) Gamma-aminobutyric acid type A
receptor point mutation increases the affinity of compounds for the
benzodiazepine site. Proc Natl Acad Sci U S A 88: 1421-1425. doi:
10.1073/pnas.88.4.1421. PubMed: 1847522.
39. Wieland HA, Lüddens H, Seeburg PH (1992) A single histidine in
GABAA receptors is essential for benzodiazepine agonist binding. J
Biol Chem 267: 1426-1429. PubMed: 1346133.
40. Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, et
al. (1993) Cloning of cDNA sequences encoding human alpha 2 and
alpha 3 gamma-aminobutyric acidA receptor subunits and
characterization of the benzodiazepine pharmacology of recombinant
alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-
aminobutyric acidA receptors. Molecular Pharmacology 43: 970-975.
41. Sanna E, Busonero F, Talani G, Carta M, Massa F et al. (2002)
Comparison of the effects of zaleplon, zolpidem, and triazolam at
various GABAA receptor subtypes. Eur J Pharmacol 451: 103-110. doi:
10.1016/S0014-2999(02)02191-X. PubMed: 12231378.
42. Liu QR, Lu L, Zhu XG, Gong JP, Shaham Y et al. (2006) Rodent BDNF
genes, novel promoters, novel splice variants, and regulation by
cocaine. Brain Res 1067: 1-12. doi:10.1016/j.brainres.2005.10.004.
PubMed: 16376315.
43. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M,
Persson H (1993) Multiple promoters direct tissue-specific expression
of the rat BDNF gene. Neuron 10: 475-489. doi:
10.1016/0896-6273(93)90335-O. PubMed: 8461137.
44. West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM et al.
(2001) Calcium regulation of neuronal gene expression. Proceedings of
the National Academy of Sciences U_S_A 98: 11024-11031. doi:
10.1073/pnas.191352298.
45. Alme MN, Wibrand K, Dagestad G, Bramham CR (2007) Chronic
fluoxetine treatment induces brain region-specific upregulation of genes
associated with BDNF-induced long-term potentiation. Neural Plast:
26496: 26496. PubMed: 18301726.
46. McGinty JF, Whitfield TW Jr, Berglind WJ (2010) Brain-derived
neurotrophic factor and cocaine addiction. Brain Res 1314: 183-193.
doi:10.1016/j.brainres.2009.08.078. PubMed: 19732758.
47. Xu H, Chen Z, He J, Haimanot S, Li X et al. (2006) Synergistic effects
of quetiapine and venlaxafine in preventing the chronic restraint stress-
induced decrease in cell proliferation and BDNF expression in rat
hippocampus. Hippocampus 16: 551-559. doi:10.1002/hipo.20184.
PubMed: 16652337.
48. Mintzer MZ, Griffiths RR (1999) Triazolam and zolpidem: effects on
human memory and attentional processes. Psychopharmacology (Berl)
144: 8-19. doi:10.1007/s002130050971. PubMed: 10379619.
49. del Cerro S, Jung M, Lynch G (1992) Benzodiazepines block long-term
potentiation in slices of hippocampus and piriform cortex. Neuroscience
49: 1-6. doi:10.1016/0306-4522(92)90071-9. PubMed: 1407540.
50. Maubach KA, Martin K, Choudhury HI, Seabrook GR (2004) Triazolam
suppresses the inductin of hippocampal long-term potentiation.
Neuroreport 15: 1145-1149. doi:10.1097/00001756-200405190-00013.
PubMed: 15129163.
51. Mori K, Togashi H, Kojima T, Matsumoto M, Ohashi S et al. (2001)
Different effects of anxiolytic agents, diazepam and 5-HT(1A) agonist
tandospirone, on hippocampal long-term potentiation in vivo.
Pharmacol Biochem Behav 69: 367-372. doi:10.1016/
S0091-3057(01)00546-9. PubMed: 11509193.
52. Xu JY, Sastry BR (2005) Benzodiazepine involvement in LTP of the
GABA-ergic IPSC in rat hippocampal CA1 neurons. Brain Res 1062:
134-143. doi:10.1016/j.brainres.2005.09.008. PubMed: 16266690.
53. Oliveira DR, Sanada PF, Saragossa Filho AC, Innocenti LR, Oler G et
al. (2009) Neuromodulatory property of standardized extract Ginkgo
biloba L. (EGb 761) on memory: behavioral and molecular evidence.
Brain Res 1269: 68-89. doi:10.1016/j.brainres.2008.11.105. PubMed:
19146837.
54. Balkin TJ, O’Donnell VM, Wesensten N, McCann U, Belenky G (1992)
Comparison of the daytime sleep and performance effects of zolpidem
versus triazolam. Psychopharmacology (Berl) 107: 83-88. doi:10.1007/
BF02244970. PubMed: 1589566.
55. Evans SM, Funderburk FR, Griffiths RR (1990) Zolpidem and triazolam
in humans: behavioral and subjective effects and abuse liability. J
Pharmacol Exp Ther 255: 1246-1255. PubMed: 2262904.
56. Higashima M, Kinoshita H, Koshino Y (1998) Differences in the effects
of zolpidem and diazepam on recurrent inhibition and long-term
potentiation in rat hippocampal slices. Neurosci Lett 245: 77-80. doi:
10.1016/S0304-3940(98)00178-5. PubMed: 9605489.
57. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G (2000)
GABAA receptors: immunocytochemical distribution of 13 subunits in
the adult rat brain. Neuroscience 101: 815-850. doi:10.1016/
S0306-4522(00)00442-5. PubMed: 11113332.
58. Sperk G, Schwarzer C, Tsunashima K, Fuchs K, Sieghart W (1997)
GABA(A) receptor subunits in the rat hippocampus I:
immunocytochemical distribution of 13 subunits. Neuroscience 80:
987-1000. doi:10.1016/S0306-4522(97)00146-2. PubMed: 9284055.
59. Fuchikami M, Morinobu S, Kurata A, Yamamoto S, Yamawaki S (2009)
Single immobilization stress differentially alters the expression profile of
transcripts of the brain-derived neurotrophic factor (BDNF) gene and
histone acetylation at its promoters in the rat hippocampus. Int J
Neuropsychopharmacol 12: 73-82. doi:10.1017/S1461145708008997.
PubMed: 18544182.
60. Schaaf MJ, de Jong J, de Kloet ER, Vreugdenhil E (1998)
Downregulation of BDNF mRNA and protein in the rat hippocampus by
corticosterone. Brain Res 813: 112-120. doi:10.1016/
S0006-8993(98)01010-5. PubMed: 9824681.
61. Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and
glucocorticoids affect the expression of brain-derived neurotrophic
factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15:
1768-1777. PubMed: 7891134.
62. Fuchikami M, Yamamoto S, Morinobu S, Takei S, Yamawaki S (2010)
Epigenetic regulation of BDNF gene in response to stress. Psychiatry
Investig 7: 251-256. doi:10.4306/pi.2010.7.4.251. PubMed: 21253408.
63. Mikkelsen JD, Søderman A, Kiss A, Mirza N (2005) Effects of
benzodiazepines receptor agonists on the hypothalamic-pituitary-
adrenocortical axis. Eur J Pharmacol 519: 223-230. doi:10.1016/
j.ejphar.2005.06.049. PubMed: 16125698.
64. Mikkelsen JD, Bundzikova J, Larsen MH, Hansen HH, Kiss A (2008)
GABA regulates the rat hypothalamic-pituitary-adrenocortical axis via
different GABA-A receptor alpha-subtypes. Ann N Y Acad Sci 1148:
384-392. doi:10.1196/annals.1410.044. PubMed: 19120132.
65. Castrén E, Rantamäki T (2010) The role of BDNF and its receptors in
depression and antidepressant drug action: Reactivation of
developmental plasticity. Dev Neurobiol 70: 289-297. doi:10.1002/dneu.
20758. PubMed: 20186711.
66. Sun Y, Evans J, Russell B, Kydd R, Connor B (2013) A benzodiazepine
impairs the neurogenic and behavioural effects of fluoxetine in a rodent
model of chronic stress. Neuropharmacology 72: 20-28. doi:10.1016/
j.neuropharm.2013.04.021. PubMed: 23639432.
67. Wu X, Castrén E (2009) Co-treatment with diazepam prevents the
effects of fluoxetine on the proliferation and survival of hippocampal
dentate granule cells. Biol Psychiatry 66: 5-8. doi:10.1016/j.biopsych.
2009.01.023. PubMed: 19251245.
68. Bosmann HB, Penney DP, Case KR, Averill K (1980) Diazepam
receptor: specific nuclear binding of [3H]flunitrazepam. Proceedings of
the National Academy of Sciences U S A 77: 1195-1198. doi:10.1073/
pnas.77.2.1195.
69. Dalezios Y, Matsokis N (1993) Nuclear benzodiazepine binding:
possible interaction with thyroid hormone receptors. Neurochem Res
18: 305-311. doi:10.1007/BF00969087. PubMed: 8479599.
70. Saha B, Mukherjee A, Santra CR, Chattopadhyay A, Ghosh AN et al.
(2009) Alprazolam intercalates into DNA. J Biomol Struct Dyn 26:
421-429. doi:10.1080/07391102.2009.10507257. PubMed: 19108581.
71. Chung CW, Coste H, White JH, Mirguet O, Wilde J et al. (2011)
Discovery and characterization of small molecule inhibitors of the BET
family bromodomains. J Med Chem 54: 3827-3838. doi:10.1021/
jm200108t. PubMed: 21568322.
72. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB et al. (2010)
Selective inhibition of BET bromodomains. Nature 468: 1067-1073. doi:
10.1038/nature09504. PubMed: 20871596.
73. Kouzarides T (2007) Chromatin modifications and their function. Cell
128: 693-705. doi:10.1016/j.cell.2007.02.005. PubMed: 17320507.
74. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY et al. (2006) Brain-
specific phosphorylation of MeCP2 regulates activity-dependent Bdnf
transcription, dendritic growth, and spine maturation. Neuron 52:
255-269. doi:10.1016/j.neuron.2006.09.037. PubMed: 17046689.
75. Baba A, Okumura S, Mizuo H, Iwata H (1983) The inhibition of
diazepam and gamma-aminobutyric acid of depolarization-induced
release of [14C]cysteine sulfinate and [3H]glutamate in rat hippocampal
slices. J Neurochem 40: 280-284. doi:10.1111/j.
1471-4159.1983.tb12683.x. PubMed: 6129289.
76. Fedele E, Ansaldo MA, Varnier G, Raiteri M (2000) Benzodiazepine-
sensitive GABAA receptors limit the activity of the NMDA/NO/Cyclic
GMP pathway: a microdialysis study in the cerebellum of freely moving
rats. J Neurochem 75: 782-787. PubMed: 10899955.
Benzodiazepine Effects on BDNF
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e84806
77. Khan GM, Smolders I, Ebinger G, Michotte Y (2000) Flumazenil
prevents diazepam-elicited anticonvulsant action and concomitant
attenuation of glutamate overflow. Eur J Pharmacol 407: 139-144. doi:
10.1016/S0014-2999(00)00720-2. PubMed: 11050301.
78. Morgan JI, Cohen DR, Hempstead JL, Curran T (1987) Mapping
patterns of c-fos expression in the central nervous system after seizure.
Science 237: 192-197. doi:10.1126/science.3037702. PubMed:
3037702.
79. Moore AN, Waxham MN, Dash PK (1996) Neuronal activity increases
the phosphorylation of the transcription factor cAMP response element-
binding protein (CREB) in rat hippocampus and cortex. J Biol Chem
271: 14214-14220. doi:10.1074/jbc.271.24.14214. PubMed: 8662977.
80. Ichisaka S, Katoh-Semba R, Hata Y, Ohshima M, Kameyama K et al.
(2003) Activity-dependent change in the protein level of brain-derived
neurotrophic factor but no change in other neurotrophins in the visual
cortex of young and adult ferrets. Neuroscience 117: 361-377. doi:
10.1016/S0306-4522(02)00771-6. PubMed: 12614676.
81. Berninger B, Marty S, Zafra F, da Penha Berzaghi M, Thoenen H et al.
(1995) GABAergic stimulation switches from enhancing to repressing
BDNF expression in rat hippocampal neurons during maturation in
vitro. Development 121: 2327-2335. PubMed: 7671799.
82. Raivio N, Tiraboschi E, Saarikoski ST, Castrén E, Kiianmaa K (2012)
Brain-derived neurotrophic factor expression after acute administration
of ethanol. Eur J Pharmacol 687: 9-13. doi:10.1016/j.ejphar.
2012.04.021. PubMed: 22546227.
Benzodiazepine Effects on BDNF
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e84806
